| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD0-H52H5 | Human | Human CD30 / TNFRSF8 Protein, His Tag |  |
||
| CD0-HF250 | Human | FITC-Labeled Human CD30 / TNFRSF8 Protein, Fc Tag |  |
|
|
| CD0-HF2H3 | Human | FITC-Labeled Human CD30 / TNFRSF8 Protein, His Tag |  |
|
|
| TN8-H5250 | Human | Human CD30 / TNFRSF8 Protein, Llama IgG2b Fc Tag, low endotoxin |  |
|
|
| CD0-H82E6 | Human | Biotinylated Human CD30 / TNFRSF8 Protein, Avitag™,His Tag (MALS verified) |  |
|
|
| CD0-H5250 | Human | Human CD30 / TNFRSF8 Protein, Fc Tag (MALS verified) |  |
|
|
| CD0-H5229 | Human | Human CD30 / TNFRSF8 Protein, His Tag (MALS verified) |  |
|
|
2e5 of Anti-CD30 CAR-293 cells were stained with 100 μL of 0.3 μg/mL FITC-Labeled Human CD30, His Tag (Cat. No. CD0-HF2H3) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).
Loaded Human CD30 Ligand, His Tag, low endotoxin (Cat. No. CDL-H524b) on HIS1K Biosensor, can bind Human CD30, Llama IgG2b Fc Tag, low endotoxin (Cat. No. TN8-H5250) with an affinity constant of 55.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Brentuximab vedotin | SGN-35; SGN-30; cAC-10; SGD-1010; cAC10-vcMMAE; cAC10-Val-Cit-MMAE,SGN35,SGN30,SGD1010 | Approved | Seattle Genetics, Millennium Pharmaceutical | ADCETRIS | fda | Systemic anaplastic large cell lymphoma, Hodgkin lymphoma | SEATTLE GENETICS | 2011-08-19 | Mantle cell lymphoma (MCL), Systemic anaplastic large cell lymphoma, Mycosis fungoides, Hodgkin lymphoma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| TT-11X | TT-11X | Phase Ⅰ | Tessa Therapeutics | Solid tumours, Lymphoma | Details |
| ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) | Phase Ⅱ | UNC Lineberger Comprehensive Cancer Center | Lymphoproliferative disease, Lymphoma, Non-Hodgkin's lymphoma (NHL), Immunological disorders | Details | |
| Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) | Phase Ⅰ | Immune Cell, Weifang People's Hospital | Anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma | Details | |
| Anti-CD30 monoclonal antibody BerH2 | Phase Ⅰ | Nonindustrial source, Medac | Hodgkin lymphoma | Details | |
| Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) | CBM-C30.1; CAR30-NKT; CD30ScFv-CD8-CD137-CD3zeta,CBM C30.1; CAR30 NKT | Phase Ⅱ | General Hospital of the People's Liberation Army, Cellular Biomedicine Group | Hodgkin lymphoma | Details |
| Anti-CD30 CAR T-cell therapy (University of Cologne) | Preclinical | University of Cologne | Cancer | Details | |
| Anti-CD30 CAR-T cell therapy (National Cancer Institute) | Hu30-CD28z | Phase Ⅰ | National Cancer Institute | Lymphoma | Details |
| Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) | Phase Ⅰ | Wuhan Bio-Raid Biotechnology | Lymphoproliferative disease | Details | |
| CD30 CAR-T cell therapy (Tessa Therapeutics) | Phase Ⅱ | Tessa Therapeutics | Hodgkin lymphoma | Details | |
| XmAb-2513 | XmAb-2513 | Phase Ⅰ | Xencor | T-cell lymphoblastic lymphoma, Hodgkin lymphoma | Details |
| Iratumumab | MDX-060; MAb-5F11; anti-CD30 | Phase Ⅱ | Medarex | Lymphoma, Non-Hodgkin's lymphoma (NHL), Hodgkin lymphoma | Details |
| HRS-3/A9 | HRS-3/A9; Anti-CD16/CD30 BiMAb,HRS 3/A9; Anti CD16/CD30 BiMAb | Phase Ⅱ | University of Saarland, Biotest | Hodgkin lymphoma | Details |
| CD30.CAR | CD30.CAR; H-27721 | Phase Ⅰ | Baylor College of Medicine, bluebird bio | Non-Hodgkin's lymphoma (NHL), Hodgkin lymphoma | Details |
| CD30.CAR-EBVST cell therapy (Baylor College of Medicine) | Phase Ⅰ | Baylor College of Medicine | Diffuse large B cell lymphoma, Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Posttransplant Lymphoproliferative Disorders, Classical Hodgkin Lymphoma | Details | |
| Anti-CD64-anti-CD30 bispecific monoclonal antibody (Medarex) | Phase Ⅰ | Medarex | Hodgkin lymphoma | Details | |
| Anti-CD16-anti-CD30 monoclonal antibody | Phase Ⅱ | Biotest | Hodgkin lymphoma | Details | |
| TT-11 | Phase Ⅱ | Tessa Therapeutics | Hodgkin lymphoma | Details | |
| AFM-13 | AFM-13 | Phase Ⅱ | University of Texas M. D. Anderson Cancer Center, Affimed | Mycosis fungoides, Peripheral T cell lymphoma (PTCL), Hodgkin lymphoma | Details |
| EBV-specific-CAR.CD30 | EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs | Phase Ⅰ | Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System | Non-Hodgkin's lymphoma (NHL), Hodgkin lymphoma | Details |
| MDX-1401 | MDX-1401 | Phase Ⅰ | Medarex | Hodgkin lymphoma | Details |
| Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1 | Phase Ⅰ | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai Jiaolian | Anaplastic large cell lymphoma (ALCL), Cutaneous T cell lymphoma (CTCL), Hodgkin lymphoma | Details |
This web search service is supported by Google Inc.
A-Z
